{"nctId":"NCT00073021","briefTitle":"Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis","startDateStruct":{"date":"2000-09"},"conditions":["Ulcerative Colitis"],"count":386,"armGroups":[{"label":"Asacol 2.4 g/day","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Asacol 400 mg (mesalamine)"]},{"label":"Asacol 4.8 g/day","type":"EXPERIMENTAL","interventionNames":["Drug: Asacol 800 mg (mesalamine)"]}],"interventions":[{"name":"Asacol 800 mg (mesalamine)","otherNames":[]},{"name":"Asacol 400 mg (mesalamine)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* male or female between 18 and 75 years of age;\n* have a confirmed diagnosis of ulcerative colitis with the extent varying from proctitis to pancolitis;\n* currently demonstrating moderately active disease\n\nExclusion Criteria:\n\nPatients will be excluded from admission to the study if they have/are:\n\n* a history of allergy or hypersensitivity to salicylates or aminosalicylates;\n* a history of extensive small bowel resection (\\>1/2 the length of the small intestine) causing short bowel syndrome;\n* current renal or hepatic disease;\n* participated in any drug or device clinical study within 30 days of entry;\n* currently enrolled in any other clinical study;\n* received any oral, intravenous, intramuscular, or rectally administered corticosteroids within 1 month prior to the Baseline Visit;\n* received any other topical rectal therapy during the week prior to the Screening Visit;\n* received immunomodulatory therapy including, but not limited to, 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate within 3 months prior to the Baseline Visit;\n* received a dose of mesalamine-containing compound by any route from which more than 1.6 g/day of mesalamine was available within 1 week prior to the Screening Visit (NOTE: 4 g/day of sulfasalazine and 4.5 g/day of balsalazide are equivalent to 1.6 g/day of mesalamine);\n* received antibiotics, other than topical antibiotics, within 1 week prior to the Screening Visit;\n* received aspirin (except for cardioprotective reasons up to a maximum dose of 325 mg/day) or NSAIDs within 1 week prior to the Baseline Visit;\n* if female, positive pregnancy test, or lactating.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Treatment Success Patients at Week 6, ITT (Intent to Treat) Population","description":"Treatment success defined as complete response (PGA score 0 and complete resolution of stool frequency, rectal bleeding, PFA (patient's functional assessment), normal sigmoidoscopy) or partial response (improvement from baseline PGA and improvement in 1 clinical assessment \\[stool frequency, rectal bleeding, PFA, sigmoidoscopy\\] and no worsening in any other clinical assessments)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.2","spread":null},{"groupId":"OG001","value":"71.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Ulcerative Colitis Disease Activity Index (UCDAI) at Week 6, ITT Population","description":"UCDAI - sum of clinical assessment scores (stool frequency score \\[0=normal, 1=1-2 stools \\> normal/day, 2=3-4 stools \\> normal/day, 3=5 or more stools \\> normal/day\\], rectal bleeding score \\[0=no blood seen, 1=streaks of blood with stool less than half of the time, 2=obvious blood with stool most of the time, 3=blood alone passed and PGA score \\[0=quiescent disease, 1=mild, 2=moderate, 3=severe\\]) and sigmoidoscopy score \\[0=normal, 1=mild, 2=moderate, 3=severe\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.2","spread":"0.27"},{"groupId":"OG001","value":"-3.7","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Whose Rectal Bleeding & Sigmoidoscopy Score Both Improved From Baseline to Week 6, ITT Population","description":"Rectal Bleeding - 0=no blood seen, 1=streaks of blood w/stool less than half of the time, 2=obvious blood w/stool most of the time, 3=blood alone passed Sigmoidoscopy Assessment Score - 0=normal (intact vascular pattern, no friability or granularity), 1=mild (erythema, diminished or absent vascular markings; mild granularity; friability), 2=moderate (marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations) 3=severe (spontaneous bleeding, ulcerations)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.8","spread":null},{"groupId":"OG001","value":"63.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Whose Sigmoidoscopy Score Improved From Baseline to Week 6, ITT Population","description":"Sigmoidoscopy Assessment Score (0=normal intact vascular pattern, no friability or granularity, 1=mild erythema; diminished or absent vascular markings; mild granularity; friability, 2=moderate marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations, 3=severe spontaneous bleeding, ulcerations)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":null},{"groupId":"OG001","value":"75.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With an Improvement in Stool Frequency, ITT Population, Week 6","description":"0=Normal stool frequency per day, 1=1-2 stools greater than normal per day, 2=3-4 stools greater than normal per day, 3=5 or more stools greater than normal per day","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"74.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Improvement in Rectal Bleeding, ITT Population, Week 6","description":"Rectal Bleeding (0=no blood seen, 1=streaks of blood with stool less than half of the time, 2=obvious blood with stool most of the time, 3=blood alone passed)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5","spread":null},{"groupId":"OG001","value":"78.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Improvement in Patient's Functional Assessment (PFA), ITT Population, Week 6","description":"PFA - 0=generally well, 1=fair, 2=poor, 3=terrible","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.5","spread":null},{"groupId":"OG001","value":"69.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Improvement in Physician Global Assessment (PGA)Score, ITT Population, Week 6","description":"PGA -Physician's Global Assessment - 0=quiescent disease (all parameters 0), 1=mild disease (parameters mostly 1's) 2=moderate (parameters mostly 2's), 3=severe (parameters mostly 3's) \\[parameters: combination of stool frequency, rectal bleeding, PFA \\& sigmoidoscopy findings\\] If scoring equal default to physician judgement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.5","spread":null},{"groupId":"OG001","value":"83.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 3, All Randomized Patients","description":"IBDQ-32 questions divided into 4 categories: bowel, systemic, emotional and social. Each question graded with the following responses: 1-more than ever before, 2-extremely frequently, 3-very frequently, 4-moderate increase in frequency, 5-some increase in frequency, 6-slight increase in frequency or 7-not at all/normal; 1/worst thru 7/best. Scoring 32 - 224 - higher score better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":"2.84"},{"groupId":"OG001","value":"29.8","spread":"2.60"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 6, All Randomized Patients","description":"IBDQ-32 questions divided into 4 categories: bowel, systemic, emotional and social. Each question graded with the following responses: 1-more than ever before, 2-extremely frequently, 3-very frequently, 4-moderate increase in frequency, 5-some increase in frequency, 6-slight increase in frequency or 7-not at all/normal; 1/worst thru 7/best. Scoring 32-224 - higher score better.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":"3.5"},{"groupId":"OG001","value":"40.4","spread":"3.08"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Moderate, Left-Sided Disease at Baseline Classified as Treatment Success at Week 6, All Randomized Patients","description":"Treatment success defined as complete response (PGA score 0 and complete resolution of stool frequency, rectal bleeding, PFA (patient's functional assessment), normal sigmoidoscopy) or partial response (improvement from baseline PGA and improvement in 1 clinical assessment \\[stool frequency, rectal bleeding, PFA, sigmoidoscopy\\] and no worsening in any other clinical assessments)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"71.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Treatment Success Patients at Week 3, ITT Population","description":"Treatment success defined as complete response (PGA score 0 and complete resolution of stool frequency, rectal bleeding, PFA (patient's functional assessment), normal sigmoidoscopy) or partial response (improvement from baseline PGA and improvement in 1 clinical assessment \\[stool frequency, rectal bleeding, PFA, sigmoidoscopy\\] and no worsening in any other clinical assessments)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":null},{"groupId":"OG001","value":"61.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":139},"commonTop":["Headache","Pain, Abdominal","Infection","Diarrhea","Nausea"]}}}